DATA GRAPHICS | Data Byte
FDA’s October approvals include the first CLDN18.2 mAb
Plus: Agency approves Pfizer’s hemophilia A and B mAb, and label expansions for five products
November 9, 2024 1:23 AM UTC
FDA approved six new medicines in October, including the U.S.’s first CLDN18.2-targeting cancer therapy, and expanded labels for five approved therapies.
Astellas Pharma Inc. (Tokyo:4503) has followed up is Japan approval of CLDN18.2 mAb Vyloy zolbetuximab, which marked the first approval of a therapy against the target worldwide, with an approval in the U.S. At least 32 other CLDN18.2 therapies are in clinical studies...
BCIQ Company Profiles